Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response, Published online: 21 November 2017; doi:10.1038/bjc.2017.402
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2A4m18J
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου